Merck & Company, Inc. (MRK)
Latest news, insights and market data
Market Data
AI Insights
Merck's Keytruda continues to excel in solid tumor treatments, highlighting its strong position in oncology as it prepares for potential exclusivity loss. Additionally, positive long-term data from its partnership with Moderna on a personalized cancer vaccine reinforces its innovative edge in the biopharma space. This dual focus on established and emerging therapies positions Merck well in a competitive market.
Latest News
| Title | Published |
|---|---|
Erasca Inc. (ERAS) Inspiring Confidence Through Commercial Collaborations Erasca Inc. (ERAS) Inspiring Confidence Through Commercial Collaborations | about 1 hour ago |
Why Health Care's Seasonal Tailwind Looks Especially Compelling This Year Why Health Care's Seasonal Tailwind Looks Especially Compelling This Year | about 1 hour ago |
Merck Gardasil Settlement Eases Legal Overhang And Refocuses Investor Attention Merck Gardasil Settlement Eases Legal Overhang And Refocuses Investor Attention | about 3 hours ago |
Merck (MRK) Recently Broke Out Above the 20-Day Moving Average Merck (MRK) Recently Broke Out Above the 20-Day Moving Average | about 3 hours ago |
Merck (MRK) Crossed Above the 50-Day Moving Average: What That Means for Investors Merck (MRK) Crossed Above the 50-Day Moving Average: What That Means for Investors | about 4 hours ago |
ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess | about 13 hours ago |
ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess Keytruda continues to shine in solid tumours, and other Merck & Co assets signal designs to address Keytruda's upcoming exclusivity loss. | about 13 hours ago |
Erasca Inc. (ERAS) Inspiring Confidence Through Commercial Collaborations
Erasca Inc. (ERAS) Inspiring Confidence Through Commercial Collaborations
Why Health Care's Seasonal Tailwind Looks Especially Compelling This Year
Why Health Care's Seasonal Tailwind Looks Especially Compelling This Year
Merck Gardasil Settlement Eases Legal Overhang And Refocuses Investor Attention
Merck Gardasil Settlement Eases Legal Overhang And Refocuses Investor Attention
Merck (MRK) Recently Broke Out Above the 20-Day Moving Average
Merck (MRK) Recently Broke Out Above the 20-Day Moving Average
Merck (MRK) Crossed Above the 50-Day Moving Average: What That Means for Investors
Merck (MRK) Crossed Above the 50-Day Moving Average: What That Means for Investors
ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess
ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess
ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess
Keytruda continues to shine in solid tumours, and other Merck & Co assets signal designs to address Keytruda's upcoming exclusivity loss.